ZAI LAB LTD0000006 Asset Resilience Ratio
ZAI LAB LTD0000006 asset resilience ratio. ZAI LAB LTD0000006 (1ZLB) has an Asset Resilience Ratio of 0.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 1ZLB defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ZAI LAB LTD0000006 (2021–2025)
Asset resilience ratio of ZAI LAB LTD0000006 from 2021 to 2025. This chart shows how ZAI LAB LTD0000006's Asset Resilience Ratio has changed over time. Read ZAI LAB LTD0000006 (1ZLB) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ZAI LAB LTD0000006's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZAI LAB LTD0000006 (1ZLB) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.00 Million | 0.91% |
| Total Liquid Assets | €10.00 Million | 0.91% |
Asset Resilience Insights
- Limited Liquidity: ZAI LAB LTD0000006 maintains only 0.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ZAI LAB LTD0000006 Industry Peers by Asset Resilience Ratio
Compare ZAI LAB LTD0000006's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
ZAI LAB LTD0000006 Asset Resilience Ratio by Year (2021–2025)
ZAI LAB LTD0000006 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ZAI LAB LTD0000006.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.85% | €10.00 Million ≈ $11.69 Million |
€1.17 Billion ≈ $1.37 Billion |
-26.98pp |
| 2024-12-31 | 27.83% | €330.00 Million ≈ $385.80 Million |
€1.19 Billion ≈ $1.39 Billion |
+26.26pp |
| 2023-12-31 | 1.57% | €16.30 Million ≈ $19.06 Million |
€1.04 Billion ≈ $1.21 Billion |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€1.22 Billion ≈ $1.43 Billion |
-- |
| 2021-12-31 | 27.64% | €445.00 Million ≈ $520.25 Million |
€1.61 Billion ≈ $1.88 Billion |
-- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more